205 related articles for article (PubMed ID: 35384378)
21. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer.
Nakayama N; Nakayama K; Shamima Y; Ishikawa M; Katagiri A; Iida K; Miyazaki K
Cancer; 2010 Jun; 116(11):2621-34. PubMed ID: 20336784
[TBL] [Abstract][Full Text] [Related]
22. Reduced RBX1 expression induces chromosome instability and promotes cellular transformation in high-grade serous ovarian cancer precursor cells.
Bungsy M; Palmer MCL; Jeusset LM; Neudorf NM; Lichtensztejn Z; Nachtigal MW; McManus KJ
Cancer Lett; 2021 Mar; 500():194-207. PubMed ID: 33290867
[TBL] [Abstract][Full Text] [Related]
23. Targeting Therapeutic Resistance and Multinucleate Giant Cells in CCNE1-Amplified HR-Proficient Ovarian Cancer.
Bai S; Taylor SE; Jamalruddin MA; McGonigal S; Grimley E; Yang D; Bernstein KA; Buckanovich RJ
Mol Cancer Ther; 2022 Sep; 21(9):1473-1484. PubMed ID: 35732503
[TBL] [Abstract][Full Text] [Related]
24. Proteogenomic analysis of Inhibitor of Differentiation 4 (ID4) in basal-like breast cancer.
Baker LA; Holliday H; Roden D; Krisp C; Wu SZ; Junankar S; Serandour AA; Mohammed H; Nair R; Sankaranarayanan G; Law AMK; McFarland A; Simpson PT; Lakhani S; Dodson E; Selinger C; Anderson L; Samimi G; Hacker NF; Lim E; Ormandy CJ; Naylor MJ; Simpson K; Nikolic I; O'Toole S; Kaplan W; Cowley MJ; Carroll JS; Molloy M; Swarbrick A
Breast Cancer Res; 2020 Jun; 22(1):63. PubMed ID: 32527287
[TBL] [Abstract][Full Text] [Related]
25. Rsf-1, a chromatin remodelling protein, interacts with cyclin E1 and promotes tumour development.
Sheu JJ; Choi JH; Guan B; Tsai FJ; Hua CH; Lai MT; Wang TL; Shih IeM
J Pathol; 2013 Mar; 229(4):559-68. PubMed ID: 23378270
[TBL] [Abstract][Full Text] [Related]
26. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers.
Karst AM; Jones PM; Vena N; Ligon AH; Liu JF; Hirsch MS; Etemadmoghadam D; Bowtell DD; Drapkin R
Cancer Res; 2014 Feb; 74(4):1141-52. PubMed ID: 24366882
[TBL] [Abstract][Full Text] [Related]
27. Ccne1 Overexpression Causes Chromosome Instability in Liver Cells and Liver Tumor Development in Mice.
Aziz K; Limzerwala JF; Sturmlechner I; Hurley E; Zhang C; Jeganathan KB; Nelson G; Bronk S; Fierro Velasco RO; van Deursen EJ; O'Brien DR; Kocher JA; Youssef SA; van Ree JH; de Bruin A; van den Bos H; Spierings DCJ; Foijer F; van de Sluis B; Roberts LR; Gores GJ; Li H; van Deursen JM
Gastroenterology; 2019 Jul; 157(1):210-226.e12. PubMed ID: 30878468
[TBL] [Abstract][Full Text] [Related]
28. Amplicon-dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer.
Etemadmoghadam D; George J; Cowin PA; Cullinane C; Kansara M; ; Gorringe KL; Smyth GK; Bowtell DD
PLoS One; 2010 Nov; 5(11):e15498. PubMed ID: 21103391
[TBL] [Abstract][Full Text] [Related]
29. Protein expression and methylation of DNA repair genes hMLH1, hMSH2, MGMT and BRCA1 and their correlation with clinicopathological parameters and prognosis in basal-like breast cancer.
Alkam Y; Mitomi H; Nakai K; Himuro T; Saito T; Takahashi M; Arakawa A; Yao T; Saito M
Histopathology; 2013 Nov; 63(5):713-25. PubMed ID: 24004112
[TBL] [Abstract][Full Text] [Related]
30. CCNE1 amplification is associated with liver metastasis in gastric carcinoma.
Kim B; Shin HC; Heo YJ; Ha SY; Jang KT; Kim ST; Kang WK; Lee J; Kim KM
Pathol Res Pract; 2019 Aug; 215(8):152434. PubMed ID: 31178228
[TBL] [Abstract][Full Text] [Related]
31. A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome.
Vargas HA; Veeraraghavan H; Micco M; Nougaret S; Lakhman Y; Meier AA; Sosa R; Soslow RA; Levine DA; Weigelt B; Aghajanian C; Hricak H; Deasy J; Snyder A; Sala E
Eur Radiol; 2017 Sep; 27(9):3991-4001. PubMed ID: 28289945
[TBL] [Abstract][Full Text] [Related]
32. Cyclin-dependent kinase 2 is an ideal target for ovary tumors with elevated cyclin E1 expression.
Yang L; Fang D; Chen H; Lu Y; Dong Z; Ding HF; Jing Q; Su SB; Huang S
Oncotarget; 2015 Aug; 6(25):20801-12. PubMed ID: 26204491
[TBL] [Abstract][Full Text] [Related]
33. Pathogenesis and heterogeneity of ovarian cancer.
Kroeger PT; Drapkin R
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):26-34. PubMed ID: 27898521
[TBL] [Abstract][Full Text] [Related]
34. GCN-5/PGC-1α signaling is activated and associated with metabolism in cyclin E1-driven ovarian cancer.
Guo T; Li B; Gu C; Chen X; Han M; Liu X; Xu C
Aging (Albany NY); 2019 Jul; 11(14):4890-4899. PubMed ID: 31313989
[TBL] [Abstract][Full Text] [Related]
35. Boosting the apoptotic response of high-grade serous ovarian cancers with CCNE1 amplification to paclitaxel in vitro by targeting APC/C and the pro-survival protein MCL-1.
Raab M; Kobayashi NF; Becker S; Kurunci-Csacsko E; Krämer A; Strebhardt K; Sanhaji M
Int J Cancer; 2020 Feb; 146(4):1086-1098. PubMed ID: 31286496
[TBL] [Abstract][Full Text] [Related]
36. Frequent CCNE1 amplification in endometrial intraepithelial carcinoma and uterine serous carcinoma.
Kuhn E; Bahadirli-Talbott A; Shih IeM
Mod Pathol; 2014 Jul; 27(7):1014-9. PubMed ID: 24309323
[TBL] [Abstract][Full Text] [Related]
37. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
Sieuwerts AM; Look MP; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; de Weerd V; Portengen H; Klijn JG; Foekens JA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3319-28. PubMed ID: 16740753
[TBL] [Abstract][Full Text] [Related]
38.
Kawahara N; Yamada Y; Kobayashi H
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070839
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-107 induces cell cycle arrests by directly targeting cyclin E1 in ovarian cancer.
Tang Z; Fang Y; Du R
Biochem Biophys Res Commun; 2019 Apr; 512(2):331-337. PubMed ID: 30885433
[TBL] [Abstract][Full Text] [Related]
40. Cyclin E as a potential therapeutic target in high grade serous ovarian cancer.
Kanska J; Zakhour M; Taylor-Harding B; Karlan BY; Wiedemeyer WR
Gynecol Oncol; 2016 Oct; 143(1):152-158. PubMed ID: 27461360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
